Doxycycline versus Doxycycline and Rifampin in Undifferentiated Spondyloarthropathy, with Special Reference to Chlamydia-Induced Arthritis. A Prospective, Randomized 9-Month Comparison.
This is the first study to demonstrate therapeutic benefit with antimicrobials to a chronic inflammatory arthritis possibly secondary to persistent Chlamydia.
....... it is far too soon for any Alzheimer's patients to be prescribed this regimen outside of a clinical trial. Despite the early result's statistical significance, questions remain about whether the drugs would make a difference in patients' lives. And, because this was the first human trial, the data need to be replicated in a much larger study.
Posted: Wed Jul 14, 2004 7:25 am Post subject:
I posted on July 1st under General Discussions, on the thread Chlamydia Pneumoniae about not getting too overly excited about all that. If you go there, you'll find my postings. I saw where folks were getting really excited, and I didn't want to put a damper on anything (as you'll see from my post), but I shared some information so people wouldn't get too excited, in case their hopes were dashed.
I was afraid word of mouth about this was creating more hype than what Dr. Sriram himself intended.
On another thread (I don't recall where exactly now - maybe the one on minocycline itself?), I posted where my PCP had mentioned to me (he's also on staff at Vanderbilt) how they had gotten pretty excited about their initial findings, but were not able to replicate the results with any real consistency or success. (I live here in Nashville.)
I think, though, that Dr. Sriram's research into C. Pneumoniae is still going on, it's just that there are no conclusive results yet that he can even speculate on at this time, nor anything anywhere indicative enough that he would recommend taking antibiotics for MS treatment. That's not to say it might not be helpful, but so far, there is nothing "earth shattering" yet.
CLINICAL TRIALS IN MULTIPLE SCLEROSIS
The following studies are being conducted by the Division of Neuroimmunology:
"A phase III clinical trial of Avonex for secondary progressive multiple sclerosis" - Biogen trial
"A phase III clinical trial of Copaxone therapy for primary progressive multiple sclerosis" - Promise trial
"Cytokine regulation of CNS demyelination" - National Multiple Sclerosis Society
"Analysis of association between C. pneumoniae and MS" - National Multiple Sclerosis Society
"Defining an oral therapeutic for multiple sclerosis" - National Institutes of Health
"IL-3R activation of microglia in CNS demyelination" - National Institutes of Health
To contact the Neuroimmunology Division or for questions regarding clinical protocols call:
The Vanderbilt Multiple Sclerosis Clinic and Research Center.
OddDuck wrote:On another thread (I don't recall where exactly now - maybe the one on minocycline itself?), I posted where my PCP had mentioned to me (he's also on staff at Vanderbilt) how they had gotten pretty excited about their initial findings, but were not able to replicate the results with any real consistency or success. (I live here in Nashville.)
Users browsing this forum: No registered users